Dewpoint Therapeutics, Inc. — Form D

Dewpoint Therapeutics, Inc. of BOSTON, MA, a company, filed a Form D exempt-offering notice with the SEC on 2020-11-02. The offering totals $77.1M, of which $77.1M was reported sold. Industry: Biotechnology.

Offering

Issuer

Officers, directors & promoters (40)

Showing 25 of 40 people.

NameRoleLocation
Srinivas H Akkaraju, M.D.DirectorBoston, MA
Oliver H Brandicourt, M.D.DirectorBoston, MA
Giuseeppe H Ciaramella, Ph.D.DirectorBoston, MA
Jurgen A Eckhardt, M.D.DirectorBoston, MA
Richard A Young, Ph.D.DirectorBoston, MA
Bruce H BeutelExecutive OfficerBoston, MA
Amir H NashatExecutive OfficerBoston, MA
Regina Barzilay, Ph.D.DirectorBoston, MA
Regina Barzilay, Ph.D.Related PersonBoston, MA
Guiseppe A Ciaramella, Ph,D.DirectorBoston, MA
Mark A Murcko, Ph.D.DirectorBoston, MA
Amir H Nashat, Ph.D.DirectorBoston, MA
Olivier Brandicourt, M.D.DirectorBoston, MA
Olivier Brandicourt, M.D.Related PersonBoston, MA
Elisabeth A LeidermanExecutive OfficerBoston, MA
Ameet Nathwani, M.D.DirectorBoston, MA
Ameet Nathwani, M.D.Executive OfficerBoston, MA
Ameet Nathwani, M.D.Related PersonBoston, MA
Isaac A Klein, M.D., Ph.D.Executive OfficerBoston, MA
Srinivas Akkaraju, M.D., Ph.D.DirectorBoston, MA
Srinivas Akkaraju, M.D., Ph.D.Related PersonBoston, MA
Lori A EscobedoExecutive OfficerBoston, MA
Fabio H Pucci, Ph.D.DirectorBoston, MA
Anthony A Hyman, Ph.D.DirectorBoston, MA
Giuseppe H Ciaramella, Ph.D.DirectorBoston, MA

Other filings by this issuer (3)

FiledFormOfferingSold
2026-07-13D/A$82.3M$77.2M
2025-09-23D$59.1M$59.1M
2022-02-04D$150.0M$150.0M

More